|1.||Ridker, Paul M: 33 articles (05/2015 - 08/2003)|
|2.||Kjekshus, John: 28 articles (12/2015 - 10/2005)|
|3.||Wikstrand, John: 26 articles (12/2015 - 10/2005)|
|4.||Ballantyne, Christie M: 24 articles (11/2014 - 01/2003)|
|5.||McMurray, John J V: 23 articles (12/2015 - 11/2007)|
|6.||Raichlen, Joel S: 23 articles (11/2015 - 05/2004)|
|7.||Elisaf, Moses S: 22 articles (05/2015 - 09/2005)|
|8.||Stein, Evan A: 20 articles (11/2015 - 02/2002)|
|9.||Glynn, Robert J: 19 articles (05/2015 - 11/2008)|
|10.||Nicholls, Stephen J: 18 articles (08/2015 - 04/2006)|
10/01/2009 - "Rosuvastatin has been reported to be beneficial in the treatment of dyslipidemia. "
01/18/2012 - "We evaluated the potential efficacy of alternate-day dosing of 10mg rosuvastatin compared with daily dosing of 10mg rosuvastatin with regarding to lipid and inflammatory markers in patients with dyslipidemia. "
11/01/2012 - "In this study, we assessed the efficacy of rosuvastatin in NASH patients with dyslipidemia. "
02/01/2009 - "To compare the efficacy of administering rosuvastatin on a daily basis versus on an alternate day basis for the treatment of dyslipidemia. "
01/01/2004 - "In a broad spectrum of adult patients with dyslipidemias, oral rosuvastatin 5-40 mg once daily effectively and rapidly improved lipid profiles in several large, randomized, mainly double-blind, multicenter trials of up to 52 weeks' duration. "
05/01/2004 - "Rosuvastatin is a highly efficacious statin, and the Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin (METEOR) study is designed to assess the impact of rosuvastatin on carotid IMT progression in low risk subjects with signs of subclinical atherosclerosis. "
04/01/2010 - "This subgroup analysis of the METEOR study showed that in middle-aged adults with sub-clinical atherosclerosis, rosuvastatin treatment resulted in significant reduction in mean maximum CIMT progression in four quartiles of baseline CIMT, with no evidence for difference in benefit across levels of baseline CIMT."
04/01/2010 - "The placebo-controlled Measuring Effects on intima-media Thickness: an Evaluation Of Rosuvastatin (METEOR) study showed significant reduction in the progression rate of maximum CIMT with 2 years of lipid treatment in asymptomatic individuals with subclinical atherosclerosis. "
04/30/2010 - "Here we planned another trial, the Justification for Atherosclerosis Regression Treatment (JART) study, to clarify the efficacy of intensive lipid-lowering therapy with rosuvastatin in Japanese with atherosclerosis. "
03/01/2007 - "The GALAXY Program is a series of clinical studies investigating the efficacy and tolerability of rosuvastatin in line with the hypothesis that the statin with the greatest efficacy for improving the atherogenic lipid profile and beneficially modifying inflammatory markers will also slow progression of atherosclerosis and improve cardiovascular outcomes. "
04/01/2011 - "Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia. "
07/15/2004 - "Thus, our findings suggest that treatment with rosuvastatin in patients with hypercholesterolemia may lead to a significant reduction in plasma ADMA levels, which appear to be related to the improvement in endothelial function by rosuvastatin."
11/01/2007 - "In conclusion, long-term treatment with rosuvastatin 40 mg is safe and effective in patients with severe hypercholesterolemia."
08/01/2013 - "This study examined whether the ABCG2 421C>A polymorphism and variants in other genes potentially related to the pharmacokinetics of rosuvastatin influenced the plasma concentration of rosuvastatin in Chinese patients with hypercholesterolemia. "
01/01/2011 - "Published studies randomized trials with rosuvastatin treatment for at least 4 weeks in hypercholesterolemia patients were used for model building and validation. "
04/01/2014 - "Rosuvastatin also reduced cardiac inflammation and oxidative tissue damage, reduced epididymal fat mass, and improved adipose tissue lipolysis much more in the CRP-transgenic strain than in the nontransgenic strain. "
07/01/2014 - "The present study demonstrates that rosuvastatin pretreatment ameliorates EBI after SAH through the attenuation of oxidative stress and NF-κB-mediated inflammation."
01/01/2014 - "This study was aimed to investigate the usefulness of (18)F-FDG-PET to differentiate vascular inflammation and to determine the effect of rosuvastatin. "
01/01/2012 - "In this study, we tested the hypothesis that chronic exposure to NP will aggravate AD-induced CKD through increasing generations of inflammation, ROS, and apoptosis that could be attenuated by rosuvastatin. "
06/01/2015 - "Rosuvastatin can mediate modest but clinically apparent anti-inflammatory effects with modification of vascular risk factors in the context of high-grade autoimmune inflammation of AS. "
01/01/2015 - "This study suggests that the CYP2C9 polymorphism may be involved in the lipid-lowering efficacy of rosuvastatin in patients with hyperlipidemia."
01/01/2015 - "This study aimed to evaluate the associations of CYP2C9 genetic polymorphism with the efficacy and safety of rosuvastatin in Chinese patients with hyperlipidemia. "
12/10/2013 - "The aim of the present study is to investigate the occurrence of an enhanced effect of bergamot-derived polyphenolic fraction (BPF) on rosuvastatin-induced hypolipidemic and vasoprotective response in patients with mixed hyperlipidemia. "
08/21/2003 - "The Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial is planned to examine the effects of rosuvastatin treatment in preventing cardiovascular events in 15,000 healthy subjects with elevated hs-CRP levels in the absence of overt hyperlipidemia."
01/01/2015 - "A total of 218 patients with hyperlipidemia were selected and treated with 10 mg rosuvastatin per day for 12 weeks. "
|1.||Highly Active Antiretroviral Therapy (HAART)
|4.||Transplantation (Transplant Recipients)